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The Association between the Measles, Mumps, and Rubella Vaccine and the
Development of Autism: A Meta-Analysis
Rashad Carlton
ABSTRACT
Autism is a childhood developmental disorder characterized by impaired social
interaction, difficulty with verbal and nonverbal communication and limited activities.
The root cause of autism is unknown. However it has been postulated that administration
of the measles, mumps, and rubella (MMR) vaccine may be causally related to the
development of autism. MMR vaccination is a requirement for entry into schools, so any
increase in adverse events associated with the vaccine carries widespread public health
importance.
The primary objective of this study was to conduct a meta-analysis of the
association between the MMR vaccination and the development of autism. The metaanalysis was limited to studies with an experimental design, unvaccinated control group,
and odds ratio or relative risk as the effect measure. Both the fixed effects and random
effects models were applied.
A total of 29 studies were identified for possible inclusion in the meta-analysis.
After applying the inclusion/exclusion criteria seven studies were included in the metaanalysis. The pooled treatment effect was weighted based on the width of the 95%
confidence interval for each of the individual studies. The pooled effect measure for the
seven studies was 1.052 (95% CI: 0.973, 1.138) (P=0.202).
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An association between the MMR vaccine and the development of autism was not
found in this analysis. Public health initiatives should continue to support mandatory
vaccination with MMR for entry into school and steps should be taken to eliminate any
barriers to vaccination. Further epidemiological studies are needed to assess the root
cause of autism.
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Introduction
Autism
Autism is a developmental disorder characterized by impaired social interaction,
difficulty with verbal and nonverbal communication, and limited activities and interests
(NINDS 2006). Autism was first characterized in 1943 by Dr. Leo Kanner of Johns
Hopkins Hospital, who termed the disease early infantile autism after studying a group of
11 children (Strock 2007). The Diagnostic and Statistical Manual of Mental Disorders
(DSM –IV) classifies autism as one disease in a class of developmental disorders referred
to as autism spectrum disorders (ASDs) or pervasive developmental disorders (PDDs)
(Strock 2007, NINDS 2006). Asperger syndrome, Rett syndrome, childhood
disintegrative disorder, and pervasive developmental disorder not otherwise specified
along with autism make up the ASDs. Autism is the most common of the ASDs with an
estimated three to six children out of 1,000 developing the disorder (NINDS 2006).
The most common sign of autism is impaired social interaction. Autistic children
usually do not know how to play interactively with other children (NINDS 2006).
Autistic children commonly have difficulty learning and understanding the normal giveand-take of social interaction. Autistic children are typically slow to learn to interpret
what others are thinking or feeling. At times they may appear to be indifferent to others.
This lack of social interaction results in the perception that they prefer to be alone (Strock
2007).
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Other common signs include problems with verbal and nonverbal communication,
repetitive behavior, and obsessive interests (NINDS 2006). In some cases autistic
children remain mute their entire life. Some autistic children develop verbal skills at a
much later age than their peers. Others will develop skills at a normal age but have
difficulty communicating with others (Strock 2007). Additionally, autistic children often
engage in repetitive behavior such as rocking or twirling (NINDS 2006). In most cases
autistic children need and seek consistency in their environment. The smallest changes
in daily routines can be very disturbing for autistic children.
In addition to the developmental challenges associated with autism, autistic
children are at higher risk for several comorbid conditions including fragile X syndrome,
tuberous sclerosis, epileptic seizures, Tourette syndrome, learning disabilities, and
attention deficit disorder. Fragile X syndrome is an inherited form of mental retardation
named for the part of the X chromosome that has a defective piece that appears pinched
and fragile when viewed under a microscope. Tuberous sclerosis is a genetic disorder
that causes benign tumors to grow in the brain and other vital organs (Strock 2007).
Approximately 20 to 30% of autistic children will develop epileptic seizures by
adulthood (NINDS 2006). In most cases the seizures can be controlled with
pharmacologic therapy. Most autistic children will have some degree of learning
disability, with the degree of disability varying by child. Often times, some areas of
ability are normal, while one or more areas will show developmental delay.
The diagnosis of autism is challenging as autism varies widely in symptoms.
Symptoms can range from mild to severe. Parents are often the first to notice any
symptoms of autism in their child. There are several screening tools that can assist in the

2

screening for autism such as the Checklist of Autism in Toddlers, the Screening Tool for
Autism in Two-Year-Olds and the Social Communication Questionnaire (Strock 2007).
In order to establish an accurate diagnosis of autism, a comprehensive evaluation is
required (NINDS 2006). The evaluation should be performed by a multidisciplinary
team consisting of a psychologist, neurologist, psychiatrist and speech therapist (NINDS
2006). Evaluation tools such as the Autism Diagnosis Interview Revised and the Autism
Diagnostic Observation Schedule help in evaluating a child for autism. The Autism
Diagnosis Interview Revised is a structured interview of 100 questions consisting of four
major factors: communication, social interaction, repetitive behaviors, and age of onset.
The Autism Diagnostic Observation Schedule is an observational measure used to detect
behaviors that are absent, delayed, or abnormal in children (Strock 2007).
The National Institute of Neurological Disorders and Stroke list the following
core behaviors that doctors rely on for a diagnosis of autism:
•

Impaired ability to make friends with peers

•

Impaired ability to initiate or sustain a conversation with others

•

Absence or impairment of imaginative and social play

•

Stereotyped, repetitive, or unusual use of language

•

Restricted patterns of interest that are abnormal in intensity or focus

•

Preoccupation with certain objects or subjects

•

Inflexible adherence to specific routine or rituals
The diagnosis of autism is often complicated by other autism spectrum disorders.

Children with insufficient symptoms to meet the criteria for autism are often classified as
having pervasive developmental disorder not otherwise specified. Children with
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Asperger syndrome present with autistic symptoms but have well developed language
skills (NINDS 2006). Tools such as the Autism Spectrum Screening Questionnaire, the
Australian Scale for Asperger’s Syndrome, and the Childhood Asperger Syndrome Test
can help to distinguish Asperger syndrome from autism (Strock 2007). Children with
childhood disintegrative disorder develop normally and then deteriorate between the
ages of 3 to 10, showing significant autistic symptoms (NINDS 2006). After a diagnosis
of autism is made, the next step is to identify appropriate treatment for the autistic child.
Currently there is no cure for autism and there is no single best treatment regimen
for all children. Current therapy is designed to alleviate specific symptoms and improve
functional ability. Treatment falls into two broad categories: educational/behavioral
interventions and pharmacologic therapy. Educational interventions include skilloriented sessions to help children develop social and language skills along with family
counseling for parents and siblings of autistic children. Pharmacologic therapy includes
antidepressants to treat depression, anxiety, or obsessive compulsive disorder or antipsychotics to treat severe behavioral symptoms (NINDS 2006).
The selective serotonin reuptake inhibitors such as fluoxetine, sertaline, and
fluvoxamine are commonly used off-label to treat depression, anxiety, and obsessive
compulsive disorder in autistic children. In 2004, the Food and Drug Administration
issued a “black box warning” alerting the public of the increased risk of suicidal ideation
or suicide attempts in children and adolescents taking antidepressants. In October 2006,
the Food and Drug Administration approved risperidone for the symptomatic treatment
of irritability in autistic children, representing the first drug with an FDA approved
indication to treat symptoms in autism (Strock 2007).
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In cases where autistic children

experience seizures, anticonvulsants are indicated. Commonly prescribed
anticonvulsants include: carbamazepine, lamotrigine, topiramate, and valproic acid.
Autistic children with attention deficit disorder or hyperactivity can be treated with
stimulant drugs, such as methylphenidate (Strock 2007). There are also several
controversial therapies available, but few if any have been scientifically proven to be
effective (NINDS 2006).
The root cause of autism is unknown to date, and as of yet a biological marker for
autism has not been found. Several causative factors have been offered including
genetics, environmental factors, abnormal levels of serotonin or other neurotransmitters
in the brain, and vaccine administration. It is strongly suspected that genetics plays
some role because families with one autistic child have an approximately 5 percent risk
of autism in a second child, which is much higher than the risk in the general population
(NINDS 2006). MRI studies of the brain have shown that many areas of the brain are
abnormal in autism including the cerebellum, cerebral cortex, limbic system, corpus
callosum, basal ganglia, and brain stem. Research is ongoing to study what role these
areas of the brain have in the development of autism along with the possible role of
neurotransmitters such as serotonin, dopamine, and epinephrine (Strock 2007).
In the past few years there has been widespread public concern regarding a
proposed theory that autism was linked to vaccine administration. The proposed link
between autism and vaccines was first reported by Wakefield and colleagues in a case
series study of 12 children with chronic enterocolitis and regressive developmental
disorder (Wakefield 1998). In 8 of the 12 children, the onset of behavioral problems was
retrospectively linked to the measles, mumps, rubella (MMR) vaccination by a parent or
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physician. The Wakefield study gave rise to the proposed association of the MMR
vaccine and the development of autism and created a major debate on the safety of the
MMR vaccination. Since the publication of the Wakefield study, several other studies
have been conducted assessing the association between MMR vaccination and the
development of autism. Due to a lack of randomized controlled trials and conflicting
results, there has not been enough evidence to support or definitively refute the
hypothesized association between MMR and autism.

Measles, Mumps, Rubella
Measles
Since the inception of vaccinations for measles, mumps, and rubella the number
of cases of these diseases has decreased by 99%. The success of the vaccinations has led
to an attempt to eliminate these diseases. A goal of the 1993 Childhood Immunization
Initiative was to eliminate indigenous transmission of measles and rubella in the United
States by 1996 (CDC 1998). While these goals have not yet been achieved it appears that
vaccination makes these goals feasible in the near future.
The first of these three diseases- measles also referred to as rubeola- is a disease
characterized by a total body skin rash. Measles is a highly contagious disease with an
incubation period of 10-12 days from exposure to prodrome and 14 days from exposure
to rash. In the United States 1-2 out of every 1,000 cases results in death. Infants and
young children are at higher risk of death from measles and its complications. The most
severe complications of measles infection are pneumonia and acute encephalitis. The
rate of death from measles in less developed countries can be as high as 25%. In 1963
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the first measles vaccine was licensed. Prior to this time an average of 400,000 measles
cases were reported each year in the United States. Since the inception of the measles
vaccine, the number of cases of measles has decreased by 99% (CDC 1998). Measles
experienced a resurgence in the United States from 1989 to 1991. There were more than
55,000 cases of measles and over 120 measles related deaths.

The resurgence was led to

a large degree by a number of unvaccinated preschool aged children residing in urban
areas.
In 1989 the Advisory Committee on Immunization Practices (ACIP) and the
American Academy of Pediatrics (AAP) recommended that all children receive two
doses of a measles-containing vaccine. The implementation of the vaccination policy led
to a decrease in the number of measles cases from 2,237 cases in 1992 to only 312 cases
in 1993. The challenges to eliminating and sustaining the elimination of measles are: 1)
continuing to vaccinate all children aged 12-15 months with a first dose of MMR, 2)
ensuring that all children have received a second dose of MMR before entering school,
and 3) working with other countries to achieve measles elimination goals (CDC 1998).
Mumps
Mumps is a disease characterized by bilateral or unilateral parotitis. The average
onset of mumps is 16-18 days after exposure with nonspecific symptoms such as fever,
headache, malaise, myalgia, and anorexia preceding parotitis. Approximately 15%-20%
of all mumps cases are asymptomatic and up to 50% of cases are associated with
nonspecific respiratory symptoms. The most serious complications of mumps such as
male sterility and aseptic meningitis are more likely to occur in adults than children
(CDC 1998).
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The mumps vaccine was first licensed in the United States in 1967. Since the
inception of the mumps vaccine, reported cases of mumps have decreased by 99% from
185,691 cases in 1968 to only 906 cases in 1995. State laws requiring that children be
vaccinated before school entry have significantly contributed to the decrease in reported
cases of mumps. The current two dose schedule of MMR likely further decreases the
mumps incidence by immunizing children with a second dose as not all children generate
an immune response following the first dose (CDC 1998).
Rubella
Rubella is a disease characterized by nonspecific signs and symptoms including a
pruritic rash, arthralgia, and low-grade fever. The average incubation period is 12 to 23
days and between 25-50% of all cases are subclinical. Congenital rubella syndrome
carries the risk of severe consequences such as miscarriages, stillbirth, fetal anomalies,
and therapeutic abortions. Children born with congenital rubella syndrome often have
several abnormalities including sensory deficits, ophthalmic deficits, mental retardation,
microcephaly, pulmonary artery stenosis, and atrial or ventricular septal defects (CDC
1998).
During the last major outbreak of rubella in the United States from 1964-1965,
there were an estimated 20,000 cases of congenital rubella syndrome from 1964-1965.
This led to the first rubella vaccine being licensed in 1969 with a target of children in
kindergarten and the early grades of elementary school. Following the initial vaccination
campaign, cases of congenital rubella decreased by 69% from 1970 to 1976. However,
rubella outbreaks continued to occur in older adolescents and young adults. ACIP
modified the recommendations for immunization to include the vaccination of post
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pubertal girls and women in 1977. Cases of congenital rubella syndrome and rubella
have occurred at a relatively constant endemic level with an average of less than 200
cases with an occasional outbreak in persons over the age of 20 years. An accurate
incidence rate for rubella is difficult to estimate because rubella surveillance in the
United States relies on a passive system (CDC 1998).
Vaccine Preparations
Measles, mumps and rubella (MMR) vaccines are available as a combination
vaccine, as well as monovalent vaccine for each specific agent. Vaccines are also
available as a combination of measles-rubella and a combination of rubella-mumps.
Excipients included in each dose of the combined or monovalent vaccines are 0.3 mg of
human albumin, 25 µg of neomycin, 14.5 mg of sorbitol and 14.5 mg of hydrolyzed
gelatin. The measles and mumps components are live vaccines produced in chick
embryo cell culture and the live rubella vaccine is grown in human diploid cell culture
(CDC 1998).
The strain of measles used in the vaccine has changed several times since the
vaccine was first licensed in 1963. Originally, both a live and an attenuated strain of
vaccine were available. Currently, only the Enders-Edmonston strain of measles licensed
in 1968 is available in the United States. Upon vaccination the measles vaccine produces
a mild, noncommunicable infection with antibodies developing in 95% of children
vaccinated at 12 months and 98% of children vaccinated at age 15 months. Serologic and
epidemiologic evidence indicates that the vaccine produces lifelong immunity in most
persons (CDC 1998)
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The strain of rubella used in vaccines is a live strain of RA 27/3 first licensed in
1979. Serologic immunity is achieved in 95% of people aged 12 months or older who
receive at least one dose of rubella vaccine. Greater than 90% of vaccinated individuals
have protection against both clinical rubella and viremia for at least 15 years. There have
been several reports of viremic reinfection following exposure among vaccinated
individuals with low levels of detectable antibodies. Additionally, rare cases of
congenital rubella syndrome have occurred in infants born to mothers with documented
serologic evidence of rubella immunity before they became pregnant (CDC 1998).
The mumps vaccine contains the live Jeryl-Lynn strain of mumps. Vaccination
with mumps vaccine produces a subclinical infection with few side effects. In controlled
clinical trials, over 97% of those vaccinated develop measurable immunity following
vaccination. Studies in the field report that the efficacy of the vaccine ranges from 75%
to 95%. Serologic and epidemiologic evidence suggest continuing protection against
infection although the duration of immunity is unknown (CDC 1998).
Vaccine Administration
The Advisory Committee on Immunization Practices (ACIP) recommends the
combined MMR vaccine as the vaccine of choice to protect against all three diseases
unless contraindicated. Two doses should be administered separated by at least one
month in all children on or after their first birthday and in high risk adolescents and
adults. The second dose of MMR should elicit a response in the few individuals who do
not elicit an immunological response to at least one component following their first
vaccination. Administering the vaccines in combination produces a similar response to
receiving single-antigen vaccinations with measles, mumps, and rubella vaccines at
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different sites or different times. ACIP supports the administration of the MMR vaccine
at the same time as other vaccines such as diphtheria, tetanus toxoid and acellular
pertussis (DTaP), Haemophilus influenzae type b (Hib), oral polio vaccine or inactivated
polio vaccine according to the schedule to receive vaccines (CDC 1998). (See Appendix
A)
ACIP recommends that all children receive their first dose of MMR vaccine at
age 12-15 months. In certain high risk areas it is recommended that children receive their
first dose by 12 months. High risk areas are defined as:
•

A county with a large inner city population,

•

A county where a recent measles outbreak has occurred among unvaccinated

preschool-aged children, or
•

A county in which more than five case of measles has occurred among preschool-

aged children each of the last 5 years.
ACIP recommends that the second dose of MMR vaccine be administered when children
are aged 4-6 years. ACIP, the American Academy of Pediatrics (AAP), and the
American Academy of Family Physicians (AAFP) have jointly adopted the
recommended timing of the second dose of MMR. ACIP encourages all states to adopt
the two dose MMR requirement for preschool-aged children so that all 50 states will
have a universal policy requiring:
•

For preschool-aged children: documentation of at least one dose of MMR vaccine

administered on or after the first birthday, and
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•

For children in kindergarten through grade 12: documentation of two doses of

MMR vaccine separated by at least 28 days with the first dose administered no earlier
than the first birthday (CDC 1998).
ACIP recommends that all people born in 1957 or later who do not have a
contraindication to the MMR vaccine should receive at least one dose. People born
before 1957 are considered to be immune to measles, mumps, and rubella. People
considered being at high risk such as international travelers, persons attending colleges,
and persons who work at healthcare facilities should receive special consideration for
vaccination. Additionally, all women of childbearing age who do not have acceptable
evidence of rubella immunity should be offered vaccinations whenever they contact the
healthcare system (CDC 1998).
MMR Adverse Events
The range of adverse effects following the administration of the MMR vaccine
ranges from common adverse events such as local pain and edema to the rare case of
anaphylaxis. An expert committee at the Institute of Medicine determined that evidence
supports a causal relationship between MMR vaccination and anaphylaxis,
thrombocytopenia, febrile seizures, and acute arthritis (CDC 1998). Other adverse events
reported in the MMR package insert include: vasculitis, otitis media, conjunctivitis, optic
neuritis, ocular palsies, Guillan-Barre syndrome and ataxia (M-M-R II 2007).
In response to the adverse events caused by all vaccines including the MMR
vaccine, The National Vaccine Injury Compensation Program (VICP) was created by the
National Childhood Vaccine Injury Act of 1986. VICP works to resolve vaccine injury
claims by providing compensation for people found to be injured by certain vaccines.
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The US Department of Health and Human Services, the US Department of Justice, and
the US Court of Federal Claims all have a role in VICP. Compensation for injured
parties as a result of vaccine administration is determined by the US Court of Federal
Claims (HRSA). VICP covers the following vaccines:
•

Diptheria, tetanus, pertussis (DTaP)

•

Haemophilus influenzae type b

•

Hepatitis A and Hepatitis B

•

Human Papillmovirus

•

Influenza

•

Measles, mumps, rubella (MMR)

•

Meningococcal

•

Polio

•

Pneumococcal conjugate

•

Rotavirus

•

Varicella
Any person who has received a vaccine covered by VICP that believes that they

were injured as a result of that vaccine may file a claim. To file a claim the effects of the
injury must have: 1) lasted for more than 6 months after the vaccine was given; or 2)
resulted in a hospital stay and surgery; or 3) resulted in death. There is no limit on the
amount of compensation an injured party may receive. The amount compensated is
determined as a reasonable amount for past and future medical and custodial care costs
and related expenses, lost earnings, reasonable lawyer fees and up to $250,000 for actual
and projected pain and suffering. A claim must be filled within 3 years after the first
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symptom of the vaccine related injury or within 2 years of death or 4 years after the first
symptom of the vaccine related injury (HRSA 2008).
Since the inception of VICP there have been 774 claims against the MMR
vaccine. A total of 271 cases resulted in compensation being paid to the claimant, 323
claims were dismissed, and 180 claims are still pending. Since 1989, there have been
2,865 claims filed for non-autism related injuries and 5,263 claims for autism related
injuries across all vaccinations. Since 1990, only one autism case has been deemed
compensable to date and 350 cases have been dismissed (HRSA 2008). The remaining
autism-related cases are still awaiting a ruling. The debate of whether autism is causally
linked to vaccine administration and therefore should be compensated under VICP is still
ongoing and has a potentially significant impact on public health.
Table 1. National Vaccine Injury Compensation Program-Post 1988 Statistics Report of
Petitions Filed
Fiscal Year

Non-Autism

Autism

Total

FY 1989

1

0

1

FY 1990

29

0

29

FY 1991

118

0

118

FY 1992

186

0

186

FY 1993

137

0

137

FY 1994

106

0

106

FY 1995

179

0

179

FY 1996

84

0

84

FY 1997

103

0

103

FY 1998

116

0

116

FY 1999

405

1

406

FY 2000

161

0

161

FY 2001

196

18

214

FY 2002

189

768

957

FY 2003

152

2,437

2,589

FY 2004

126

1,088

1,214

FY 2005

146

587

733

FY 2006

154

169

323

FY 2007

238

168

406

FY 2008

39

27

66

2,865

5,263

8,128

Total
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Table 2. National Vaccine Injury Compensation Program Post 1988 Statistics Report for
Adjudications of Claims
Non-Autism

Autism

Fiscal Year
Compensable Dismissed

SubTotal

Compensable Dismissed

SubTotal

Total

FY 1990

2

0

2

0

0

0

2

FY 1991

10

22

32

0

0

0

32

FY 1992

30

43

73

0

0

0

73

FY 1993

22

57

79

0

0

0

79

FY 1994

41

43

84

0

0

0

84

FY 1995

48

51

99

0

0

0

99

FY 1996

50

78

128

0

0

0

128

FY 1997

60

51

111

0

0

0

111

FY 1998

53

72

125

0

0

0

125

FY 1999

38

73

111

0

0

0

111

FY 2000

67

75

142

0

0

0

143

FY 2001

66

79

145

0

0

0

145

FY 2002

98

95

193

0

4

4

197

FY 2003

52

74

126

0

21

21

148

FY 2004

60

120

180

0

113

113

293

FY 2005

60

69

130

0

51

51

181

FY 2006

67

76

145

0

107

107

249

FY 2007

80

71

151

0

32

32

183

FY 2008

21

9

30

1

22

23

53

Totals

924

1,158

2,082

1

350

351 2,433

Thimerosal
A second hypothesis dealing with vaccine administration and the development of
autism contends that thimerosal, a mercury containing preservative that has been used in
some vaccines and other pharmaceutical products since the 1930s, is the agent causing
autism. Thimerosal was contained in over 30 childhood vaccines including Haemophilus
influenzae type b, hepatitis B, and DTaP up until 1999. Thimerosal was never used as a
preservative for the MMR vaccine because thimerosal would inactivate the live vaccine.
The thimerosal hypothesis gained credibility after FDA researchers determined that the
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childhood vaccination schedule might expose children to cumulative doses of ethylmercury that exceed some federal safety guidelines (IRSC 2004). In 2001, the Institute
of Medicine concluded that the evidence was inadequate to accept or reject a causal
relationship between exposure to thimerosal and the development of autism (IRSC 2004).
As of March 2001, all formulations of vaccines for childhood immunizations are free of
thimerosal (IRSC 2004).

Healthy People 2010
Healthy People 2010 is a declaration of the national health objectives designed to
identify the most significant preventable threats to health and to establish national goals
to reduce these threats. The two primary goals of Healthy People 2010 are to increase the
quality and duration of healthy life and to eliminate health disparities. There are 28 focus
area chapters in Healthy People 2010 and each chapter contains a concise goal statement.
The goal of Healthy People 2010 pertaining to immunizations and infectious disease is to
prevent disease, disability, and death from infectious diseases, including vaccine
preventable diseases (Healthy People 2010).
Healthy People 2010 includes specific goals and objectives under each chapter
outlining goals and methods for improving health. The overall goal of Chapter 14:
Immunization and Infectious Diseases, is to reduce or eliminate indigenous cases of
vaccine-preventable diseases. Healthy People 2010 attempts to build upon the progress
that was made toward meeting the Healthy People 2000 objectives. As an example, the
number of cases of measles decreased from 3,396 indigenous cases in 1988 to only 74
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cases in 1998 (Healthy People 2010). A primary objective under this goal is the
elimination of all cases of measles, mumps, and rubella.
The achievement of a high level of coverage for two doses of MMR vaccine
makes the goal of eliminating measles, mumps, and rubella feasible. In 1998 the baseline
immunization rate for at least one dose of the MMR vaccine was 92%. The Healthy
People 2010 goal is to maintain at least 90% coverage for one dose of the MMR vaccine.
It is believed that coverage of at least 90% is sufficient to prevent the circulation of
viruses and bacteria-causing disease. However, even with the achievement of 90%
coverage levels it is imperative to monitor subgroups of the population that are under
vaccinated. These groups of under vaccinated individuals increase the possibility of a
major outbreak of a vaccine preventable disease. Eliminating potential health disparities
is a necessary measure to achieving the goal of eliminating all cases of measles, mumps,
and rubella (Healthy People 2010).
Another objective of the chapter on immunization and infectious diseases from
Healthy People 2010 that builds upon Healthy People 2000 is to maintain vaccination
coverage levels for children in licensed day care facilities and children in kindergarten
through the first grade. The goal for the MMR vaccine is 95% for children in day cares
and children in kindergarten to first grade. As measured in Healthy People 2000, the
individual coverage rates for three or more doses of polio, three or more doses of
diphtheria/tetanus/acellular pertussis (DTaP), one or more doses of MMR and three or
more doses of Haemophilus influenzae type b vaccines were each at or above 91 percent
(Health People 2010). Increasing the coverage rate to 95% for all children entering a
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licensed day care facility or entering school represents a significant step to eliminating all
cases of vaccine preventable diseases.
Healthy People 2010 also outlines strategies to achieve the outlined goals and
objectives. Major strategies to protect people from vaccine preventable diseases include:
•

Improving the quality and quantity of vaccination delivery services,

•

Minimizing financial burdens for needy persons,

•

Increasing community participation, education and partnership,

•

Improving monitoring of disease and vaccination coverage rates, and

•

Developing new or improved vaccines and improving vaccine use.

Programs such as Vaccines for Children and SCHIP have made vaccinations available
for children. These programs along with the requirements of vaccinations for entry into
day care and schools have increased the vaccination rate (Healthy People 2010).
Improvements in the vaccination rate not only extend benefits to those that are
vaccinated, benefits of vaccination are gained by society as a whole. In cases where a
few people cannot be vaccinated, if the vaccination level in the community is high these
people are protected due to group or “herd” immunity, whereby the unvaccinated group
has a decreased risk of contracting a disease because all those around them have been
vaccinated. Achievement of the Healthy People 2010 MMR vaccination goals will go a
long way toward eradicating measles, mumps, and rubella.
It is hypothesized that administration of the MMR vaccine is causally related to
the development of autism. The hypothesis was first proposed by Wakefield and
associates (Wakefield1998) following a case study of 12 children with gastrointestinal
disorders and developmental regression. In 8 of the 12 children, the parents or the

18

physician retrospectively linked the onset of the behavioral problems with the
administration of the MMR vaccine. While the authors concluded that there was
insufficient evidence in their study to support a causal relationship, the study generated a
hypothesis warranting further research. The purpose of this research is to evaluate if a
causal relationship exists between childhood vaccination with MMR and the development
of autism by applying the statistical methods of a meta-analysis of published primary
literature.
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Methods
The primary objectives of this analysis are to:
1. Assess the causal relationship between the MMR vaccine and the development of
childhood autism, and
2. Discuss the impact of the association of the MMR vaccine and the development
of autism on the ACIP vaccination guidelines and the Healthy People 2010 goal
for immunizations against preventable diseases.
A quantitative meta-analysis was conducted to assess the causal relationship
between the MMR vaccine and the development of autism. A comprehensive literature
search of PubMed and Medline assessing the relationship between the MMR vaccine and
the development of autism during the years 1998 to 2007 was conducted. Key search
terms for the systematic literature review included: autism, autistic, MMR, measles,
mumps, and rubella alone or in combination. The search was limited to articles published
in the English language. A total of 29 studies were identified.
The following study inclusion criteria were employed on the 29 studies.
1. Appropriate study design (e.g. prospective or retrospective case-control or cohort
study
2. Study must contain a control group
3. Study endpoints must report or allow for the calculation of the effect measure and
a standard error or confidence interval for the association of MMR vaccination
and the development of autism (odds ratio or relative risk)

20

4. Experimental group must have received MMR vaccination
5. Adequate sample size (n≥100)
The following study exclusion criteria were employed:
1. Study does not have an unvaccinated comparison group (e.g. case report/case
series)
2. Study endpoints do not allow for the calculation of an odds ratio or relative risk
3. Study exposure does not include the MMR vaccination
4. Study is not independent of another study included in the analysis (e.g. re-analysis
of the same study population)
After applying the inclusion/exclusion criteria seven studies remained for
inclusion in the meta-analysis (see Appendix B). Statistical analyses combining and
interpreting the results of independent studies were conducted to integrate the results of
several studies and arrive at a conclusion on the causal association of the MMR vaccine
and autism.
The patient population included children (<18 years) who have received the
MMR vaccine under a normal vaccination schedule according to ACIP guidelines or
appropriate guidelines for their country.
Study Endpoints will include:
•

Effect measure
o Odds ratio/relative risk for each individual study
o Pooled effect for the association between MMR vaccination and the
development of autism

•

Meta-regression

21

o Meta-regression to assess the impact of continuous predictors (e.g. age at
vaccination, number of vaccinations)
The odds ratio of the association between the MMR vaccine and the development
of autism was measured for each individual study as the effect measure. The pooled
effect measure was then calculated based on the weighted average of the effect measures
seen in each study. The weight for each study was determined based on the width of the
95% confidence interval for the effect measure of each study. The meta-analysis was
conducted using both a fixed and a random effects model.

A sensitivity analysis was

conducted to assess the impact of individual studies on the pooled effect measure.
Publication bias was assessed using a funnel plot and the trim and fill technique. Data
analysis will be conducted using Comprehensive Meta Analysis (CMA) Version 2.0, a
computer program for meta analysis developed by a team of experts from the US and
U.K. and funded by the US National Institutes of Health.
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Results
Descriptive Statistics
Seven out of 29 studies met all inclusion/exclusion criteria. Fifteen studies were
excluded due to the lack of an unvaccinated control group (Studies 1, 2, 3, 5, 6, 9, 12, 13,
15, 16, 17, 21, 22, 27, and 28). Three studies were excluded for the lack of MMR
exposure in the study (Studies 7, 11, and 25). Three studies were excluded because they
did not allow for the calculation of an effect size (Studies 18, 19, and 29). One study was
excluded because it was a secondary analysis of a previous study that was included in the
meta-analysis (Study 4).
The following seven studies were included in the meta-analysis: Madsen 2002,
Honda 2005, Smeeth 2004, Taylor 1999, Uchiyama 2007, Goldman 2004 and Taylor
2002.
Table 3. Synopsis of Included Studies
Study
Madsen 2002

Design

Retrospective
cohort study
Honda 2005
Cohort study
Smeeth 2004
Case-control
study
Taylor 1999
Epidemiological
study
Uchiyama 2007 Epidemiological
study
Goldman 2004 Retrospective
cohort study
Taylor 2002
Population
study

Country

Years

Denmark

1991-1998

Dependent
Variable
Autism or ASD

Japan
United
Kingdom
United
Kingdom
Japan

1988-1996
1987-2001

ASD
Autism or ASD

1979-1992

Autism

1976-1999

ASD

Denmark

1980-1992

Autism

United
Kingdom

1979-1992

Autism
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Madsen 2002 was a retrospective cohort study of all children born in Denmark
including a total of 537,303 children. Vaccination status was obtained from the National
Board of Health and information on autism status was obtained from the Danish
Psychiatric Central Register. A total of 316 children were diagnosed with autism and 422
with an autism spectrum disorder. The relative risk for autistic disorder in the
unvaccinated group compared to the vaccinated group was 0.919.
Honda 2005 was a cohort study of children up to age seven born between 1988
and 1996 in Kohoku Ward of Japan. All children born in 1993 or after did not receive a
single vaccination of MMR. The cumulative incidence of autism spectrum disorders
increased significantly in the birth cohorts from 1988 through 1996 with the most notable
increase beginning with the 1993 birth cohort. The odds ratio for the association between
MMR and autism was 1.921.
Smeeth 2004 was a matched case-control study using the U.K. General Practice
Research Database. Cases were people born in 1973 or later who were diagnosed with a
pervasive developmental disorder, between 1987 and 2001. Controls were matched on
age, sex, and general practice. A total of 1294 cases and 4469 controls were included in
the study. The odds ratio for the association of MMR and autism was 0.880.
Taylor 1999 was an epidemiological study of children from eight North Thames
health districts in the U.K. Information from clinical records of the children was linked
to immunization data held on the child health computing system. Any clustering of onset
of autism in post vaccination periods were investigated using the case series method. A
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total of 498 cases of autism were identified. The odds ratio for the association of MMR
and the development of autism was 0.940.
Uchiyama 2007 was an epidemiological study of the association between MMR
vaccination and the development of autism in Japan. Since the MMR vaccine was only
used in Japan between 1989 and 1993, this time period affords a natural experiment for
MMR and autism. The study included an analysis on 904 patients with autism spectrum
disorder. The analysis included cohorts from three periods: before, during, and after
MMR usage. There were no significant differences in the incidence of autism in the
cohort that received MMR and those who had not with an odds ratio of 0.744.
Goldman 2004 investigated the prevalence of autism by age category from 1980
to 2002 using a nationwide computerized registration system with the Danish Psychiatric
Central Register. The MMR vaccine was added to the immunization schedule of
Denmark in 1987. Linear regression analysis was used to investigate compare the
periods preceding and following the introduction of the MMR vaccine. Longitudinal
trends in the prevalence data suggest a temporal association between the introduction of
MMR vaccine and the rise in autism with an odds ratio of 4.700.
Taylor 2002 was a population study with case note review of five health districts
in north east London. The study population included 278 children with core autism and
195 with atypical autism identified from computerized disability registers born between
1979 and 1998. The odds ratio for the association of MMR and the development of
autism was 0.980.
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Meta-Analysis Results
Two of the seven studies included in the meta-analysis suggested a causal
association between MMR and autism and five studies did not suggest a causal
association. The combined effect measure using a fixed effects model was 1.052 (95%
CI: 0.973, 1.138; p value= 0.202). The weights assigned for the studies based on the size
of the confidence intervals under a fixed model were: 6.99% for Madsen 2002, 5.22% for
Honda 2005, 8.35% for Smeeth 2004, 3.04% for Taylor 1999, 1.13% for Uchiyama
2007, 3.43% for Goldman 2004, and 71.84% for Taylor 2002. When using a random
effects model, the combined effect measure was 1.267 (95% CI: 0.879, 1.827; p
value=0.204). In the random effects model the studies weights were: 15.31% for Madsen
2002, 14.81% for Honda 2005, 15.56% for Smeeth 2004, 13.55% for Taylor 1999,
10.08% for Uchiyama 2007, 13.87% for Goldman 2004, and 16.82% for Taylor 2002.

Figure 1. Meta-analysis results: Autism and MMR

Study name

Statistics for each study
Odds Lower
ratio
limit

Madsen 2002
Honda 2005
Smeeth 2004
Taylor 1999
Uchiyama 2007
Goldman 2004
Taylor 2002

0.919
1.921
0.880
0.940
0.744
4.700
0.980
1.052

0.684
1.365
0.672
0.601
0.357
3.084
0.894
0.973

Upper
limit

Odds ratio and 95% CI

Z-Value p-Value

1.234
2.704
1.153
1.471
1.551
7.163
1.075
1.138

-0.563
3.743
-0.928
-0.271
-0.789
7.199
-0.430
1.276

0.574
0.000
0.354
0.787
0.430
0.000
0.667
0.202
0.01

0.1

No Association

Meta Analysis
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Figure 2. Meta-analysis results: Funnel Plot
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Sensitivity Analysis
The meta-analysis was conducted removing the outlier study, Goldman 2004, in
the sensitivity analysis. The combined effect measure for the 6 studies excluding
Goldman 2004 was 0.998 (95% CI: 0.921, 1.080; p value=0.953) when using a fixed
effects model. When using a random effects model the combined effect measure was
1.035 (95% CI: 0.835, 1.281; p value=0.755). The funnel plot assessing publication bias
revealed no publication bias as the studies were symmetrical. Most studies assessing the
association between MMR and the development of autism fall in the range of no
association. The Goldman 2004 and Honda 2005 studies fall outside of the funnel,
indicating that they were outliers.
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Discussion
The results of this meta-analysis did not find a causal association between MMR
vaccination and the development of autism. The combined fixed effect measure of 1.052
includes a 95% CI from 0.973 to 1.138 that crosses one, thus making the results nonsignificant. The same scenario occurs when using a random effects model with an effect
measure of 1.267 and a 95% CI from 0.879 to 1.827. In both a fixed and random effects
model the meta-analysis did not find a causal association between MMR vaccination and
the development of autism. Due to the small number of studies included the study may
not have had adequate power to detect a difference if one existed.
The two studies included in the meta-analysis that supported an association
between MMR vaccination and the development of autism are potentially biased by time.
Goldman 2004 examines the prevalence of autism by age category from 1980 to 2002
using a computerized registration system in Denmark. The study provided a comparison
of prevalence rates pre and post licensure of the MMR vaccine. Prevalence rates in the
post licensure period may have been much higher than in the pre licensure period due to
greater diagnostic awareness and an overall increasing prevalence of autism.
Studies such as Dales 2001 and Kaye 2001 have found an increasing prevalence
of autism over time. Dales 2001 was a time trend analysis of the association of autism
and MMR vaccination coverage in California. Dales 2001 showed a sustained increase in
autism cases from 44 cases per 100,000 births in 1980 to 208 cases per 100,000 live
births in 1994 with minimal change in MMR vaccination rates. The changes in the
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prevalence rates seen in this study provide evidence that MMR vaccination was not the
cause of the increased prevalence of autism. Similarly, Kaye 2001 was a time trend
analysis of autism prevalence in the UK from 1988 to 1999. The incidence of autism
increased sevenfold from 1988 to 1999 with the vaccination rate staying above 95% over
the entire timeframe. This suggests that some other factor was the root cause of the
increasing prevalence of autism and not MMR vaccination.
The association found in Honda 2005 may have been influenced by the same time
factor bias as Goldman 2004. In Honda 2005, the cumulative incidence of autism
spectrum disorders were examined from 1988 to 1996 in the Kohoku ward of Japan. The
population was divided into vaccinated and unvaccinated populations based on MMR
vaccination being discontinued in 1993. The association that was found may have been
influenced by time with the two cohorts being determined by the time when MMR
vaccination was available.
There are several possible explanations for the apparent increase in autism
prevalence. Changes in the prevalence of autism may be influenced by: substantial
migration of affected children into or out of a community, change in age of onset or
recognition, large changes in denominator population, increased ascertainment of
children with diagnoses of autism, a change in diagnostic criteria to include individuals
with milder symptoms, and a true increase in the incidence of the disease, which can be
attributable to new environmental exposures (Halsey 2001). Studies to determine the
prevalence of autism are very susceptible to bias and therefore prevalence rates in the
literature vary considerably. The increased attention and better understanding of autism
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has likely led to a greater diagnostic awareness accounting for a portion of the increased
prevalence.
Vaccination rates and vaccine safety are major issues of concern for public health.
An adequate vaccination history is routinely a requirement for school entry. Reasonable
concerns about the safety of childhood vaccines would require an examination of the
vaccine schedule and the legality of requiring children to be vaccinated before entering
school. The evidence in this case did not find a causal association between MMR
vaccination and the development of autism. As such, public health initiatives should
focus on achieving the Healthy People 2010 goals of eliminating vaccine preventable
diseases. Measles, mumps, and rubella pose significant risks to the health of
unvaccinated children. Media attention and parental concern about the safety of the
MMR vaccine has led some parents to withhold the vaccination from their child.
Disseminating evidence on the safety of the MMR vaccine should be a major public
health initiative. Educating parents on the safety of the vaccine and the potential dangers
of measles, mumps, and rubella is the first step to increasing the vaccination rate and
eventually eliminating these three diseases.
In order to adequately address the problem of autism more information is needed
on the root cause of the disease. Areas that require further study include factors
associated with autism including genetics and environmental exposure in utero and
during the first few months after birth, or temporally associated with the onset of
symptoms (Halsey 2001). One of the primary reasons that MMR vaccination was
believed to be a cause of autism was the close temporal relationship between MMR
vaccination and the onset of symptoms. According to the Recommended Vaccination
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Schedule (Table 1), the MMR vaccine is given at 12-15 months, which coincides with the
typical onset of autism. During the 12-15 months of age period, children are receiving
several vaccines that may have some role in the development of autism. Additionally,
presentation with autism at this early age would suggest that there may be genetic or in
utero factors that are causally associated with autism development. Weiss and associates
reported an association between microdeletion and microduplication on chromosome
16p11.2 (Weiss 2008). This novel microdeletion and microduplication carries a
substantial susceptibility to autism, but it only accounts for approximately 1% of all
autism cases. The identification of this one genetic factor responsible for 1% of all
autism cases may be just the beginning of uncovering the genetic link to autism.
Another area for future research is the incidence of regression in people with
autism. Wakefield and associates first hypothesized that the MMR vaccine was
associated with a ‘regressive’ phenotype of autism (Wakefield 1998). Further study on
the nature and incidence of people with ‘regressive’ autism may show a certain group of
individuals who are genetically predisposed or have some other factor that triggers
regressive autism. It may be possible that the MMR vaccine or some other
environmental exposure around the time of MMR vaccination may trigger the onset of
regressive autism.
There is the potential that a previously unrecognized infectious agent may affect
persons with autism. A close temporal relationship between MMR vaccination and onset
of autism symptoms led to the proposed causal association. In the 12-15 months of life
before MMR vaccination, children are exposed to several potentially infectious agents.
Like previous infectious diseases such as HIV, it may be years before a causative
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pathogen is identified. It is vital that continued scientific efforts be directed to the
identification of the cause or causes of autism and ways to avoid this debilitating disease.
The strengths of this study include population-based data, inclusion of an
unvaccinated control group, and large total sample size. Limitations of the study include
small number of studies included, retrospective data collection for some studies,
differences in the dependent variable, differences in vaccination policies across countries,
recording of data may have been incomplete or inaccurate, and the inability to control for
potential confounders such as time, greater diagnostic awareness and age at vaccination.
The quality of the meta-analysis is limited by the limitations of each individual study.

Conclusion
This study does not support a causal association between the MMR vaccine and
the development of autism. Public health initiatives are needed to promote the safety of
the MMR vaccine and to increase the vaccination rate. Increasing the vaccination rate for
MMR will generate progress toward eliminating measles, mumps, and rubella as
childhood diseases. Further epidemiological research on the root cause of autism should
focus on a genetic link or environmental factors in the early stages of life.
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Appendix A Recommended Immunization Schedule
Table 4. Recommended Immunization Schedule for Ages 0-6
Vaccine

Birth

Hepatitis B
Rotavirus
Diphtheria, Tetanus,
Pertussis
Haemophilus
influenzae type b
Pnuemococcal
Inactivated
Poliovirus
Influenza
Measles, Mumps,
Rubella
Varicella
Hepatitis A
Meningococcal

Hep B

1
month

2
months
Hep B
Rota
DTaP

4
months

6 months

12
15
months months
Hep B

Rota
DTaP

Rota
DTaP

Hib

Hib

Hib

Hib

PCV
IPV

PCV
IPV

PCV

PCV
IPV

18
months

19-23
months

2-3
years

4-6
years

DTaP

PPV
Yearly

MMR
Varicella
HepA (2 doses)

MMR
Hep A Series
MCV4

Key:
= Range of recommend ages
= Certain high-risk groups
Adapted from: Recommended Immunization Schedule for Persons Aged 0-6 Years- United States 2008. Approved by the Advisory Committee on Immunization
Practices, the American Academy of Pediatrics and the American Academy of Family Physicians. Available at: www.cdc.gov/vaccines.recs/shedules
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Appendix B Research Review
Table 5. Research Review
Citation

Design Information

1. Dales L,
Hammer SJ,
Smith NJ. Time
trends in autism
and MMR
immunization
coverage in
California.
JAMA
2001;285(9):
1183- 1185.

Objective: To
determine if a
correlation exists in
secular trends of
MMR immunization
coverage among
young children and
autism occurrence

Outcome Measures

Results

•
MMR
immunization
coverage rates as of 17
months and 24 months
and numbers of autism
cases, grouped by year
of birth

Methods:
Retrospective
analysis of MMR
immunization
coverage rates in
children in California
kindergartens and of
autism caseloads
among children who
were enrolled in the
California
Department of
Development
Services
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Key Assumptions/
Inclusion/
Limitations
Exclusion
No correlation was
•
Immunization Excluded
found; sustained
- Autism and
at 17 months used
increase in autism
immunization
because this is just
cases, while changes
records not
before the mean age
in immunization
linked to be
when parents first
coverage where much notice
able to
smaller and of shorter developmental
determine a
duration
control group
disorders
•
Immunization
and autism records
on the same
individuals could not
be linked

Appendix B (Continued)
2. DeFastano F,
Bhasin TK,
Thompson WW,
et al. Age at first
measles-mumpsrubella
vaccination in
children with
autism and
school-matched
control subjects:
a populationbased study in
metropolitan
Atlanta.
Pediatrics
2004;113: 259266.

Objective: To
compare age at first
MMR vaccination
between children
with autism and
children who did not
have autism

•
Odds Ratio
determined by
conditional logistic
regression

No significant
associations for any
age cutoff were found
for specific case
subgroups; More
cases than control
were vaccinated
before 36 months
(OR 1.49; OR 1.23 in
the birth certificate
cohort)

Methods: Casecontrol study using
vaccination data
abstracted from
immunization forms
for school entry
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•
MMR vaccine
increases the risk of
autism, which
usually develops
before 24 months of
age, if so then
children vaccinated
at younger ages
would have a higher
risk of developing
autism
•
Compared
cases and controls
because they did not
have an
unvaccinated group
and had incomplete
information for
determining the date
of onset of autism

Excluded
-Study did not
have a control
group that was
unvaccinated

Appendix B (Continued)
3. DeWilde S,
Carey I, Richards
N, et al. Do
children who
become autistic
consult more
often after MMR
vaccination? Br J
Gen Pract.
2001;51: 226227.

Objective: To assess
changes in parental
concern as measured
by a change in
consultation behavior
following MMR
vaccination

Methods: Casecontrol study using the
Doctor’s Independent
Network database to
count the number of
consultations
4. Farrington CP, Objective: To test the
Miller E, Taylor hypothesis that MMR
B. MMR and
vaccination causes
autism: further
autism without preevidence against specifying any fixed
a causal
time interval after
association.
vaccination in which
Vaccine 2001;19: the risk of autism
3632-3635.
might be increased

•
Number of
consultations before
and after the MMR
vaccination

No significant
differences in the
numbers of
consultations in the 6
months before and
two months after
MMR between cases
and control

•
Cases of
autism could not be
confirmed
•
Cases and
controls both
received the MMR
vaccination

Excluded
-Study does
not have an
unvaccinated
control group

•
Relative
incidence for autism
diagnosis or
regression following
MMR vaccination

In all instances the
relative incidences
did not differ
significantly from 1,
indicating no
association between
vaccination and
autism in the
subsequent risk
periods

•
Study
includes data on all
MMR vaccines,
including those
given later than the
recommended
schedules

Excluded
-Second
analysis of
same study
population;
follow-up
analysis of
Taylor et al.
(Lancet 1998)

Methods: Selfmatched case series
study
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Appendix B (Continued)
5. Fombonne E,
Zakarian R,
Bennett A, et al.
Pervasive
developmental
disorders in
Montreal,
Quebec, Canada:
prevalence and
links with
immunizations.
Pediatrics
2006;118: e139e150.

6. Geier DA,
Geier MR. A
comparative
evaluation of the
effects of MMR
immunization
and mercury
doses from
thimerosal-

Objective: To estimate
the pervasive
developmental
disorders in Montreal
from 1987 to 1998 and
to evaluate the
relationship with
changes in cumulative
exposure to
ethylmercury
(thimerosal) and trends
in MMR vaccination
use rates
Methods: Cohort study
of children born
between 1987 and 1996
using surveys of
vaccination rates and
thimerosal exposure
Objective: To evaluate
the effects of MMR
immunization and
mercury from
thimerosal-containing
vaccines on the
prevalence of autism
Methods:

•
Odds Ratio
for thimerosal
exposure
•
Odds Ratio
for MMR
vaccination use rates

No significant effects
of thimerosal
exposure on the risk
of developing a
pervasive
developmental
disorder (OR 1.39 for
exposure free vs.
exposure); No
association with
MMR, as pervasive
developmental
disorders increased
while MMR
vaccination rates
decreased (OR 1.10)

•
Children with
a PPD diagnosis
were identified by
school officials and
this diagnosis was
not verified by direct
assessment
•
Individual
immunization data
was not available

Excluded
-Study did not
have an
unvaccinated
control group
as individual
immunization
data was not
available

•
Linear
regression
coefficients
-Prevalence of
autism in relation to
average mercury
doses
-Number of doses of
primary pediatric

Close correlation
between mercury
doses from
thimerosal-containing
vaccines and
prevalence of autism;
Potential correlation
between MMR
vaccines and the

•
Examined
cohorts of children
and did not look at
individuals therefore
can only detect large
universal effects
•
Evidence to
support association
with MMR vaccine

Excluded
-Study did not
have an
unvaccinated
control group
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Appendix B (Continued)
containing
childhood
vaccines on the
population
prevalence of
autism. Med Sci
Monit.
2004;10(3):
P133-P139.
7. Geier DA,
Geier MR.
Nuerodevelopme
ntal disorders
following
thimerosalcontaining
childhood
immunizations: a
follow-up
analysis. Int J
Toxicol.
2004;23(6): 369376.

Retrospective cohort
study of the Biological
Surveillance
Summaries of the
CDC, the US
Department of
Education dataset and
the CDC’s yearly live
birth estimates
Objective: To
determine if the
previously observed
effect between
thimerosal-containing
childhood vaccines and
neurodevelopmental
disorders are still
present after children
have had time to
further mature

MMR vaccine to the
prevalence of autism
•
Odds Ratios
from average
increased mercury
exposure received
from thimerosalcontaining vaccines

prevalence of autism

is lacking (OR are
not reported)

•
Odds ratio for
development of
neurodevelopmental
disorders

Significantly
increased OR for
developmental
disorders for autism
(OR 1.8), mental
retardation (OR 2.6),
speech disorder (OR
2.1), personality
disorder (OR 2.6) and
thinking abnormality
(OR 8.2)

•
Limitations of
the Vaccine Adverse
Events Reporting
Dataset include:
underreporting,
erroneous reporting,
frequent multiple
exposures, multiple
outcomes, and lack
of precise
denominators
•
Study of
DTaP vaccine and
not MMR

Methods: Cohort study
of children receiving
thimerosal-containing
vaccines to those not
receiving thimerosalcontaining vaccines
from 1997 to 2000
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Excluded
-Study
exposure does
not include
MMR
vaccination

Appendix B (Continued)
8. Goldman GS,
Yazbak FE. An
investigation of
the association
between MMR
vaccination and
autism in
Denmark.
Journal of
American
Physicians and
Surgeons
2004;9(3): 7075.
9. Hilton S, Hunt
K, Petticrew M.
MMR:
marginalized,
misrepresented
and rejected?
Autism: a focus
group study
[abstract]. Arch
Dis Child 2007;
92: 322-327.

Objective: To compare
the prevalence of
autism in the periods
preceding an following
the introduction of the
MMR vaccine in
Denmark
Methods: Cohort study
using data from
nationwide
computerized
registration system in
Denmark
Objective: To explore
how the MMR vaccine
controversy impacted
the lives of parents
caring for children with
autism
Methods: Qualitative
focus group study
conducted in the UK

•
Linear
regression on the
prevalence of autism
by age cohorts
•
Relative Risk
of autism (adjusted
for greater
diagnostic
awareness)

RR of autism
following
introduction of MMR
vaccine is 8.5 and
adjusted risk is 4.7;
suggests a temporal
association between
the introduction of
the MMR vaccine
and the rise in autism

•
Parent’s
perception of the
MMR vaccine and
their response to the
controversy
surrounding the
vaccine and autism

Many parents felt the
vaccine could be too
potent for children
who are susceptible
to developing autism;
Many felt guilty that
they may have
contributed to their
child’s autism
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•
The 20-24
year old cohort
potentially could
have received the
monovalent vaccine
as toddlers and the
MMR booster dose
when it became
available
•
Adjusted RR
is highly sensitive to
the increasing trend
during 3 years, 1990
to 1992
•
Nonexperimental design
(focus group study)

Included

Excluded
-Study does
not have an
unvaccinated
control group
(nonexperimental
design)

Appendix B (Continued)
10. Honda H,
Shimizu Y,
Rutter M. No
effect of MMR
withdrawal on
the incidence of
autism: a total
population study.
J Child Psychol
Psychiatry
2005;46(6): 572579

Objective: To compare
autism frequency
before and after the
termination of the
MMR vaccination
program

11. Hviid A,
Stellfeld M,
Wohlfahrt J,
Melbye M.
Association
between
thimerosalcontaining
vaccine and
autism. JAMA
2003; 290(13):
1763- 1766.

Objective: To
determine whether
vaccination with a
thimerosal-containing
vaccine is associated
with development of
autism

Methods: Analysis of
annual trends in autism
spectrum disorder
incidence in Japan

•
MMR
vaccination rates and
the corresponding
incidence of autism
cases
•
Risk factor
analysis using
logistic regression

The incidence of
autism increased in
birth cohorts both
before and after
MMR vaccinations
were discontinued;
statistically
significant increase in
autism incidence after
the discontinuation of
the MMR vaccination
program

•
RR for autism
and other autisticspectrum disorders,
including trend with
dose of ethylmercury

Risk of autism did
not differ
significantly between
children vaccinated
with thimerosalcontaining vaccines
and those without
(RR 0.85 for autism;
RR 1.12 for autisticspectrum disorders)

Methods: Cohort study
of all children born in
Denmark from 1990 to
1996 comparing
children vaccinated

No evidence of a
dose response (RR
45

•
In Japan
children only receive
one dose of MMR as
opposed to the initial
vaccination and a
booster shot as is the
custom in most
countries
•
Provides
epidemiological data
on the effect of the
removal of the MMR
vaccine
(hypothesized
offending agent)
•
Examined
children vaccinated
with a thimerosalcontaining
formulation of the
pertussis vaccine
compared with
pertussis vaccine
without thimerosal

Included

Excluded
-Study
exposure does
not include
MMR
vaccination

Appendix B (Continued)
with a thimerosalcontaining vaccine and
a thimerosal-free
vaccine formulation
12. Kaye JA,
Objective: To estimate
Melero-Montes
the changes in the risk
M, Jick H.
of autism and assess
Mumps, measles, the relation of autism to
and rubella
the MMR vaccine
vaccine and the
incidence of
Methods: Time trend
autism recorded
analysis of data from
by general
the UK general practice
practioners: a
research database
time trend
(GRPD)
analysis. BMJ
2001;322: 460463.

0.98)

•
Annual and
age specific
incidence for first
recorded diagnosis
of autism and
coverage rates for
the MMR vaccine

Incidence of autism
increased sevenfold
in the birth cohorts,
while the vaccine
coverage rate
remained above 95%;
Suggests no
association between
MMR vaccine and
autism incidence
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•
Initially
intended to do a
case-control study,
but only 3% of cases
and controls were
not vaccinated
•
Did not obtain
and evaluate full
clinical record
information from
general practioners
to describe more
fully the
characteristics of
children diagnosed
with autism

Excluded
-Study does
not contain an
unvaccinated
control group

Appendix B (Continued)
13. Madsen KM,
Vestergaard M.
MMR
vaccination and
autism: What is
the evidence for
a causal
association?
Drug Safety
2004;27(12):
831-840.
14. Madsen KM,
Hviid A,
Vestergaard M,
et al. A
population-based
study of measles,
mumps, and
rubella
vaccination and
autism. N Eng J
Med.
2002;347(19):
1477-1482.

Objective: To study
the evidence on MMR
vaccines and the
occurrence of autism
with particular focus on
the epidemiological
literature
Methods: Literature
review
Objective: To evaluate
the hypothesized
association of MMR
vaccine and autism

•
Case series
•
Case-control
studies
•
Ecological
studies
•
Crosssectional studies
•
Cohort studies

Review of the
literature does not
support a causal
relationship between
MMR vaccines and
autism; No primates
models exist and the
biologic plausibility
remains questionable

•
Literature
review that identified
10 epidemiological
studies with none
reporting a causal
association

Excluded
-Study does
not contain
an
unvaccinated
control group

•
Relative risk
of autistic disorder

The RR of autistic
disorder was 0.92
and the RR of
another autismspectrum disorder
was 0.83; strong
evidence against a
causal association

•
Exposure data
was collected
prospectively,
independent of
parental recall and
before the diagnosis of
autism
•
Assumed that
the data on MMR
vaccination is
complete because
practioners in
Denmark are
reimbursed only after
reporting immunizations to the National
Board of Health

Included

Methods:
Retrospective cohort
study of all children
born in Denmark from
January 1991 to
December 1998
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Appendix B (Continued)
15. Makela A,
Nuorti JP,
Peltola H.
Neurologic
disorders after
measles-mumpsrubella
vaccination.
Pediatrics
2002;110: 957963.

Objective: To assess
whether an association
prevails between MMR
vaccination and
encephalitis, aseptic
meningitis and autism

16. Parker SK,
Schwartz B,
Todd J,
Pickering LK.
Thimerosalcontaining
vaccines and

Objective: To assess
the quality of evidence
assessing a potential
association between
thimerosal-containing
vaccines and autism

Methods:
Retrospective cohort
study of individual
MMR vaccination data
from a hospital
discharge register of
children vaccinated
between November
1982 and June 1986

•
Total number
of hospitalizations
for autism after
MMR vaccination
during the study
period
•
Number of
events within 3
month risk intervals
post-vaccination
compared with the
number expected for
encephalitis and
aseptic meningitis

Did not detect any
clustering of
hospitalizations for
autism after
vaccination; Did not
identify any
association between
MMR vaccination
and encephalitis,
aseptic meningitis,
and autism

•
10
epidemiological
studies and 2
pharmacokinetic
studies of
ethylmercury

Studies do not
demonstrate a link
between thimerosalcontaining vaccines
and autism, and the
pharmacokinetics of
ethylmercury make
48

•
Follow-up was
extended to the end of
the study for each
child vaccinated
because of the
undefined latency of
disease
•
Authors did not
have access to
outpatient records and
not all autism cases are
treated as inpatients
•
Exact incidence
of autism could not be
determined because
autism develops subtly
over long periods of
time and some patients
may be effected at
birth but not
symptomatic until later
in life
•
Results of
epidemiological
studies have several
inherent limitations
such as: differences in
study population,
multiple potential

Excluded
-Study did
not have an
unvaccinated
control group

Excluded
-Study does
not have an
unvaccinated
control group

Appendix B (Continued)
autism spectrum
disorder: a
critical review of
published
original data.
Pediatrics
2004;114: 793804.
17. Patja A,
Davidkin I,
Kurki T, et al.
Serious adverse
events after
measles-mumpsrubella
vaccination
during a
fourteen-year
prospective
follow-up.
Pediatr Infect
Dis J.
2000;19(12):
1127-1134.

Methods: Literature
review of original
published articles from
1996 to 2004

Objective: To
distinguish events
having a causal relation
with MMR vaccination
from those with only a
temporal relation

•
Serious
adverse events
following MMR
vaccination (no time
frame was imposed)

Methods: Prospective
follow-up study using a
passive surveillance
system launched by the
Finnish National Board
of Health
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such an association
less likely

sources of bias, and
the potential effects of
confounding

30 cases of
anaphylaxis were
reported and febrile
seizures were the
most commonly
reported event;
There were no cases
of autism associated
with MMR
vaccination during
the 14 year period

•
Lack of a
control group due to a
near fully vaccinated
population
•
The 14 year
follow-up allows for
ample time to identify
cases of autism in the
3 million vaccine
doses

Excluded
-Study does
not have an
unvaccinated
control group

Appendix B (Continued)
18. Richler J,
Luyster R, Risi
S, et al. Is there a
‘regressive
phenotype’ of
autism spectrum
disorder
associated with
the measlesmumps-rubella
vaccine? A
CPEA study. J
Autism Dev Dis
2006; 36(3):
299-316.

Objective: To assess
whether a new
phenotype of regressive
autism is present and to
assess the association
with MMR vaccination
Methods: A multi-site
case-control study
using data collected
from 10 sites across the
US as part of the
Collaborative Program
for Excellence in
Autism (CPEA)

•
Analyses
from the initial ADIR and algorithm
scores from the most
recent ADI-R and
ADOS as well as
standard scores from
the Vineland
Adaptive Behavior
Scales and verbal
and non-verbal IQ
scores
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Findings of present
study provides no
evidence that
regression in autism
is associated with
MMR vaccination;
Much like children
with autism in
general, children
with autism and
regression are a
heterogeneous group
with varying
trajectories of
development

•
Children with
autism and regression
should have more
social and
communicative skills
prior to loss but still
show signs of atypical
early development
•
Children with
regressive autism
should show different
outcomes in terms of
social and
communicative skills
•
If regressive
autism is associated
with GI symptoms,
then regressive autism
patients should have
more GI disorders/
symptoms than normal
autism patients
•
Age at onset of
autistic symptoms
should more closely
follow age at MMR
vaccination
•
Limitation was

Excluded
-Study
endpoints do
not allow for
the
calculation of
a RR or OR
for the
association of
MMR and
autism

Appendix B (Continued)

19. Smeeth L,
Hall AJ,
Fombonne E, et
al. A casecontrol study of
autism and
mumps-measlesrubella
vaccination using
the general
practice research
database: design
and
methodology.
BMC Public
Health 2001; 1:2.

Objective: To
determine if autistic
children are more likely
to have received MMR
vaccination prior to
disease onset and to
examine whether there
is any association
between clinical onset
of disease and the
timing of MMR
vaccination
Methods: A matched
case-control study
using data derived from
the UK General
Practice Research
Database

•
Conditional
logistic regression to
assess the
association between
MMR vaccination
and autism (Odds
ratio)
•
Case series
analyses to estimate
the relative
incidence of autism
in defined time
intervals after
vaccination

51

No results reported

that information about
child’s early
development was
provided by
retrospective parent
report, which is open
to bias
•
Copies of all
hospital summaries
will be requested to
validate the diagnosis
of autism

Excluded
-Study does
not allow for
the
calculation of
an OR or RR
for the
association of
MMR and
autism

Appendix B (Continued)
20. Smeeth L,
Cook C,
Fombonne E, et
al. MMR
vaccination and
pervasive
developmental
disorders: a casecontrol study.
Lancet 2004;364:
963-969.

Methods and
objectives described
above

21. Takahashi H,
Suzumura S,
Shirakizawa F, et
al. An
epidemiological
study of Japanese
autism concerning
routine childhood
immunization
history. Jpn J
Infect Dis.
2003;56: 114-117.

Objective: To assess
the causal association
of autism with the
MMR vaccine

Described above

The OR for the
association between
MMR and pervasive
developmental
disorder was 0.86
(0.68-1.09)
suggesting no
association between
MMR vaccination
and increased risk of
pervasive
developmental
disorders

•
Logistic
regression analysis
(Odds ratio)

Methods: A casecontrol study of
adjusted logistic
regression analysis on
subjects growing up in
the Tokyo area
between 1988 and
52

The OR for
monovalent measles
immunization (OR
5.33), non-mumps
immunization (OR
8) and non-rubella
immunization (OR
8.57) with the
development of
autistic spectrum
disorders; Suggests a
decreased risk of

•
Case reports
were obtained for 87%
of patients to validate
the diagnosis of a
pervasive
developmental
disorder
•
Limitation was
that when children
joined a participating
general practice after
the date of MMR
vaccination, their
previous vaccination
history was recorded
retrospectively
•
Only 21 cases
were enrolled in the
study
•
Results may be
biased by the informed
consent process, which
may have discouraged
caregivers from
enrolling children with
a poor or incomplete
immunization history
•
Compared

Included

Excluded
-Study did
not have an
unvaccinated
control group

Appendix B (Continued)
1992

22. Taylor B.
Vaccines and the
changing
epidemiology of
autism. Child
Care Health Dev
2006;32(5): 511519.
23. Taylor B,
Miller E,
Farrington CP, et
al. Autism and
measles, mumps,
and rubella
vaccine: no
epidemiological
evidence for a
causal
association.
Lancet 1999; 353:
2026-29.

Objective: To review
the available literature
on the association
between autism and
MMR vaccination
Methods: Literature
review and
interpretation
Objective: To
investigate whether
MMR vaccine may be
causally associated
with autism
Methods:
Epidemiological study
of children born with
autism since 1979 in
the UK using the caseseries method to
investigate the
clustering of onsets in
the post vaccination
period

•
Interpretation
of published studies
on the association
between autism and
MMR vaccination

•
Time trend
analysis
•
Relative risk
of temporal
association of
autism and MMR
vaccination
•
Case series
for temporal
association
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autism with MMR
vaccines compared
with monovalent
antigens
The recorded
prevalence of autism
has increased
considerably in
recent years. The
strong genetic
component makes a
post-natal cause
unlikely
Steady increase in
cases by year of
birth with no sudden
step up or change in
trend line; no
temporal association
between autism
onset with one or
two years of MMR
vaccination (0.94,
1.09)

MMR vaccine to
monovalent antigens
•
Diagnostic
procedures for
determining special
educational disabilities
such as autism are not
standardized nor have
they been uniform
over time

Excluded
-Study did
not have an
unvaccinated
control group

•
Diagnosis of
autism was confirmed
based on medical
records
•
Limitation was
not that the diagnosis
could not be verified
in all cases and the
ascertainment may
have been incomplete
•
Clinical notes
were of variable
quality and many did
not contain updated
information

Included
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24. Taylor B,
Miller E, Lingam
R, et al. Measles,
mumps, and
rubella
vaccination and
bowel problems
or developmental
regression in
children with
autism:
population study.
BMJ 2002;324:
393-396.

Objective: To
investigate whether
MMR vaccination is
associated with bowel
problems and
developmental
regression in children
with autism

25. Thompson
WW, Price C,
Goodson B, et al.
Early thimerosal
exposure and
neuropsychologic
al outcomes at 7
to 10 years. N
Engl J Med. 2007;
357(13): 12811292.

Objective: To assess
the association
between current
neuropsychological
performance and
exposure to mercury
during the prenatal
period, postnatal
period, and the first 7
months of life

Methods: Population
study with case note
review to
independently
recorded vaccine data

Methods: Cohort

•
Recorded
bowel problems
lasting at least three
months, age of
reported regression
and relation to
MMR vaccination
•
Single and
multivariate logistic
regression

•
Neuropsychol
ogical outcomes
associated with
thimerosal
(mercury) exposure
•
Measures of
association
measured with
ordinary leastsquares regression
and logistic
regression
54

The proportion of
children with
developmental
regression (OR 0.98)
or bowel symptoms
did not change
significantly during
the 20 years from
1979; findings
provide no support
for an MMR
associated “new
variant” form of
autism with
developmental
regression and
bowel problems
Only a few
significant
associations with
exposure to mercury
from thimerosal
were found; the
detected associations
were small and
almost equally
divided between
positive and
negative effects

•
The percentage
of patients with
regression (25%) is
likely an
overestimation
•
Limitation was
that data were not
recorded
systematically and
there was variability in
the level of detail

Included

•
Study did not
assess autismspectrum disorders
•
Mercury
exposure was
determined based on
published data and the
data from the FDA on
the vaccines that the
children received,
from HMO records,
immunization records,

Excluded
-Study
exposure did
not include
MMR
vaccination

Appendix B (Continued)
study of 1047 children
between the ages of 7
and 10 years
administered
standardized tests
assessing 42
neuropsychological
outcomes

26. Uchiyama T,
Kurosawa M,
Inaba Y. MMR
vaccination and
regression in
autism spectrum
disorders:
negative results
presented from
Japan. J Autism
Dev Disord
2007;37: 210-217.

Objective: To
investigate whether
the MMR vaccination
is associated with
“regressive autism”

•
Odds ratio for
the association
between regression
and MMR exposure

Methods: Casecontrol comparison of
children who received
and did not receive the
MMR vaccination and
the change over time
in the proportion of
children who showed
regressive symptoms
across the pre-MMR,
MMR and post-MMR
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The OR for those in
the MMR group who
received the vaccine
was 0.744 (0.3491.517); The odds
ratio for children
who did not receive
the vaccine across
the three generations
was 0.626 (0.3231.200); the rate of
regression did not
vary across the preMMR, the MMR
and the post-MMR
cohorts

and maternal interview
•
Limitations
include a potential
selection bias due to a
majority of selected
families declining to
participate and the
inability to control for
interventions such as
speech therapy that
may have biased
results toward the null
•
In Japan the
MMR vaccine was
only given between
1985 and 1991 and
thus allows for
comparison of the
before, during, and
after effect of MMR
vaccination
•
Assumed that
information in the
Maternal and Child
Handbook was
accurate as most of the
information is entered
by health professionals
•
Limitations:

Included

Appendix B (Continued)
time frames in Japan

27. Wakefield AJ,
Murch SH,
Linnell J, Casson
DM, et al. Illeallymphoid-nodular
hyperplasia, nonspecific colitis,
and pervasive
developmental
disorder in
children. Lancet
1998;351: 637641.

Objective: To
investigate a series of
children presenting
with chronic
enterocolitis and
regressive
developmental
disorder following
vaccination with the
MMR vaccine

•
Temporal
association between
symptom onset and
vaccination

Methods:
Consecutive series
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In 8 of the 12
children the onset of
behavioral problems
was linked to MMR
vaccination by the
parent or child’s
physician; Once
child received the
monovalent measles
vaccine after which
his development
slowed

study conducted in one
private clinic, the
sample size of subjects
who received the
MMR vaccine was
small, and several
issues concerning
definition and
measurement of
regression
(information was
highly dependant on
parental report using
an instrument which
asks limited questions
on regression)
•
Potential
selection bias in selfreferred group
•
Small sample
size (12 children)
•
Lack of control
group
•
Temporal
association largely
depends on parent
recall and when they
first notice signs of
developmental

Excluded
-Study did
not have an
unvaccinated
control group
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28. Wilson K,
Mills E, Ross C,
et al. Association
of autistic
spectrum disorder
and the measles,
mumps, and
rubella vaccine.
Arch Pediatr
Adoles Med.
2003;157: 628634.

analysis of 12 children
with chronic
enterocolitis and
regressive
developmental
disorder
Objective: To
systematically review
the evidence for and
against the existence
of an association
between autistic
spectrum disorder and
the MMR vaccine

regression

•
12
epidemiological
studies assessing the
association between
autistic spectrum
disorder and MMR
vaccination

Methods: Systematic
review of medical
literature to identify
all controlled
epidemiological
articles examining the
association between
autistic spectrum
disorder and MMR
vaccination
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The results of all of
the studies showed
no association
between autistic
spectrum disorders
and the MMR
vaccine

•
Studies
included: case-series,
cross-sectional studies,
case-control studies,
and retrospective
cohort studies
•
Studies varied
in how autistic
spectrum disorder was
diagnosed

Excluded
-Study did
not have an
unvaccinated
control group
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29. Woo EJ, Ball
R, Bostrom A, et
al. Vaccine risk
perception
among reporters
of autism after
vaccination:
vaccine adverse
event reporting
system 19902001. Am J
Public Health
2004; 94(6):
990-995.

Objective: To
investigate vaccine risk
perception among
reporters of autism to
the Vaccine Adverse
Event Reporting
System (VAERS)

•
Perceptions of
parents of children
with autism who
believe that
vaccinations may
have been a cause

Methods: Structured
interviews were
conducted of 124
patients who reported
autism to VAERS
between 1990 and 2001
compared to published
survey results of
parents in the general
population
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Only 15% deemed
immunizations
extremely important
for children’s health;
two-thirds had
withheld vaccines
from their children

•
Passive
surveillance systems
such as VAERS are
subject to many
limitations including:
underreporting,
incomplete
information,
inadequate
denominator data, and
lack of an unbiased
comparison group

Excluded
-Study did
not allow for
the
calculation of
an OR or RR
for the
association
between
autism and
MMR

